Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 VX-445 + tezacaftor + ivacaftor in cystic fibrosis with F508del/minimal function genotype
NL-OMON45841Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second from baseline through Week 24. Started Oct 2018; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45841.